ontyOncothyreon Inc (USA) (NASDAQ:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives and outcomes of patients, today announced that data from the company’s ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of  metastatic breast cancer, will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.

“We are looking forward to presenting additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive breast cancer, including an analysis of patients that suffer from central nervous system (CNS) metastases, at SABCS,” said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. “CNS metastases impact up to 50 percent of women with HER2-positive metastatic breast cancer and represent a major unmet medical need. ONT-380 is an exciting molecule that has the potential to provide a much needed treatment option for this patient population.”

The SABCS presentation details are as follows:

A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)

First Author: Cristiano Ferrario, Segal Cancer Centre, Jewish General Hospital, Montreal, QC
Date/Time: Friday, December 11, 2015 at 7:30-9:00 a.m. CT
Session: Poster Session 4: Treatment: HER2-Targeted Therapy
Abstract P4-14-20

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)

First Author: Rashmi Krishna Murthy, MD Anderson Cancer Center, Houston, TX
Date/Time: Friday, December 11, 2015 at 7:30-9:00 a.m. CT
Session: Poster Session 4: Treatment: HER2-Targeted Therapy
Abstract P4-14-19 (Original Source)

Shares of Oncothyreon Inc . closed last Friday at $3.46 . ONTY has a 1-year high of $4.69 and a 1-year low of $1.41. The stock’s 50-day moving average is $2.92 and its 200-day moving average is $3.20.

On the ratings front, Cantor Fitzgerald analyst Mara Goldstein maintained a Hold rating on ONTY, with a price target of $4, in a report issued on August 7. The current price target implies an upside of 15.6% from current levels. According to TipRanks.com, Goldstein has a total average return of -1.2%, a 39.6% success rate, and is ranked #2927 out of 3842 analysts.

Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.